Operating profit before amortization: Imunon (IMNN)
Uninterrupted supplies of biocomponents from leading laboratories ensure the stability of Imunon, Inc. (IMNN) trials. The EBITDA_Co trend reflects the current financial status, where the parameter value reaches 0.00. Valuation growth is driven by the success of the TheraPlas platform and Phase 2 data for ovarian cancer. Strict control over drug transportation guarantees patient safety and high precision of final clinical results.
%20Operating%20profit%20before%20deduction%20of%20amortization&width=1200&height=400&colorIndex=0&v=mwbxec28.yq-7cu2wow&start=20220704&end=20261111&filename=GURU_Markets_-_IMNN_-_Imunon-Inc._-_Operating-profit-before-deduction-of-amortization "IMNN (Imunon) Income before deduction of interest, taxes and amortization history from 11/23/2025 to 11/11/2026 | 👁️GURU.Markets👁️")
Imunon (IMNN) - metric breakdowns and financial figures
- market value and analyst target forecast:
- company stock exchange capitalization indicators:
- balance sheet net asset value indicators:
- company total debt and liquidity indicators:
- earnings and market ratios statistics:
IMNN - Company Net Income|Net Profit Forecast Imunon, Inc.|IMNN - Price to Earnings Ratio|Price to Future Earnings Ratio Imunon Inc|IMNN - PEG Multiple|Enterprise Value to Operating Income Before Depreciation Imunon|IMNN - Profit before payment of interest, taxes and amortization|Earnings per share for the last 12 months Imunon|IMNN - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth imunon.com|IMNN - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Imunon, Inc.
Fundamental company valuation:IMNN Imunon, Inc.
This metric measures the core business's net cash generation before interest and taxes, allowing investors to filter out market noise and accurately identify phases of maximum operational efficiency. By analyzing the absolute EBITDA trend, one can assess the extent to which the DNA vaccine and immunotherapy development of Imunon, Inc. (IMNN) is transforming into actual cash flow amid the progress of clinical trials.
Who Imunon, Inc. competes with
Tempus (TEM) - Profit before interest, taxes and amortization|QGEN - Profit before payment of interest, taxes and amortization|IONS (ionispharma.com) - Operating profit before amortization|RGEN (Repligen) - Operating profit before deduction of amortization|Avidity Biosciences Inc - Income before deduction of interest, taxes and amortization|CRSP (CRISPR Therapeutics Corp) - Operating profit EBITDA|GeneDx Corp (WGS) - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Ultragenyx Pharmaceutical (RARE)|beamtx.com - Operating profit before amortization|Operating profit EBITDA SRPT (Sarepta)|TWST - Operating profit before deduction of amortization|TXG: Operating profit before deduction of amortization|Operating income before deduction of amortization Intellia Corp NTLA|STOK: Operating profit EBITDA|BLFS - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Wave Life Sciences Ltd.|Operating profit before deduction of amortization Maze Therapeutics, Inc. (MAZE)|Profit before payment of interest, taxes and amortization Sionna Pharma (SION)|Prime Medicine Bio - Operating profit before amortization|Profit before payment of interest, taxes and amortization Taysha Gene Therapies TSHA|QURE: Operating profit before amortization|MeiraGTx - Operating profit EBITDA|RGNX (REGENXBIO Inc) - Operating profit before amortization|Solid Bio (SLDB) - Profit before payment of interest, taxes and amortization|Operating profit before amortization OCGN|PACB (Pacific Biosciences) - Operating profit EBITDA|Operating profit EBITDA benitec.com|Operating profit EBITDA DSGN|Operating income before deduction of amortization Rocket Pharma|Profit before payment of interest, taxes and amortization 4D Molecular Therapeutics Inc FDMT|LXEO - Operating profit before deduction of amortization|KRRO: Operating profit before deduction of amortization|EDIT - Operating profit EBITDA|Silence Therapeutics plc (SLN) - Profit before payment of interest, taxes and amortization|Operating profit before amortization PRQR|Profit before payment of interest, taxes and amortization Codexis Inc|Profit before interest, taxes and amortization Sangamo BioSciences SGMO|Profit before payment of interest, taxes and amortization Nautilus Biotechnology (NAUT)|metagenomi.co - Operating profit before amortization|Precision BioSciences, Inc. - Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization GBIO|Boundless Bio, Inc - Operating profit EBITDA|Operating income before deduction of amortization Exicure, Inc. XCUR|phiopharma.com (PHIO) - Profit before payment of interest, taxes and amortization|Operating profit before amortization MBIO|RNAZ (TransCode Therapeutics Inc.) - Operating profit EBITDA|Operating profit before deduction of amortization Bionano (BNGO)|Operating profit before deduction of amortization APDN (Applied DNA)|Operating income before deduction of amortization bluebird bio, Inc|Operating profit EBITDA IPA (ImmunoPrecise Antibodies Ltd.)|Operating income before deduction of amortization omegatherapeutics.com (OMGA)|OMIC - Profit before payment of interest, taxes and amortization|Regulus Therapeutics, Inc. (RGLS) - Operating profit before deduction of amortization|Syros (SYRS) - Profit before payment of interest, taxes and amortization|Operating profit before amortization TBIO|Profit before payment of interest, taxes and amortization TRACON Pharmaceuticals|Operating profit before amortization UBX (unitybiotechnology.com)
